Welcome to PRI

Founded in 2002, the Pharmaceutical Research Institute (PRI) at Albany College of Pharmacy and Health Sciences is a center for drug discovery and development.

PRI investigators possess expertise in fields that include nanotechnology, medicinal chemistry, molecular biology, and cell biology. Areas of focus include: hematology/oncology, cardiovascular (dyslipidemia), ophthalmology, vascular diseases, neurology, and inflammation.As part of its mission, PRI is also engaged in teaching and learning. Pharmacy students, graduate students, and visiting scholars from around the world visit the Institute to conduct research and learn the latest advances across a wide range of therapeutic areas.

Here is the Annual Research Forum Agenda: Annual Research Forum Agenda 2018

Here is the Registration link: 2018 Annual Research Forum Registration

PRI Executive Director Wins the Kuwait Prize

Congratulations Dr. Mousa !

Dr. Shaker Mousa has been named a 2017 recipient of the Kuwait Prize, one of the world’s most prestigious awards for achievements in science.

* * * Click here to view a video highlighting Dr. Mousa’s career accomplishments. * * *

Sponsored by the Kuwait Foundation for the Advancement of Sciences (KFAS), the annual award recognizes lifetime contributions of Arab scientists across the globe. Dr. Mousa was honored in the category of Applied Sciences (Applied Medical & Applied Allied Health Sciences).

Since graduating 1st in his class from the College of Pharmacy at Egypt’s Alexandria University, Dr. Mousa has dedicated his career to advancing the pharmaceutical and health sciences. He holds more than 350 U.S. and international patents, and his work has been reported in an estimated 1,000 peer reviewed publications. As a Research Scientist and Fellow at DuPont Pharmaceuticals Co. for nearly 17 years, he played a key role in the development of drugs that have been used to help tens of millions of patients, a list of which includes the popular imaging agent Cardiolite (also marketed as Miraluma).

Since being named the founding Chairman and Executive Vice President of PRI at ACPHS in 2002, Dr. Mousa has assembled a team of scientists with expertise in hematology/oncology; ophthalmology; neurology; and a range of cardiovascular and inflammatory diseases. A list of PRI’s accomplishments over the past 15 years includes:

  • Research grants and capital equipment donations totaling more than $25 million
  • Publication of more than 300 papers in peer-reviewed journals
  • Organizing various conferences and seminars, including a weeklong Nanomedicine Symposium and Workshop held on the ACPHS Campus in 2015
  • Engagement of hundreds of students in scientific research including high school, bachelor’s, master’s, Pharm.D., M.D., Ph.D., and post-doctoral students
  • Creation of the College’s 1st spinoff compnay, NanoPharmaceuticals LLC

NanoPharmaceuticals LLC, was formed in 2013 to develop Nanomedicines for the treatment of rare diseases. One of the company’s chemical compounds has already received two Orphan Drug Designations from the FDA – one for glioblastoma (a type of brain tumor) and the other for pancreatic cancer. Clinical trials are expected to begin in 2018.

It is my great honor to receive the Kuwait Prize for Applied Sciences, and I wish to thank the KFAS for using this awards program to stimulate interest in the scientific community and help inspire further advances,” said Dr. Mousa. “I truly believe that science knows no boundaries. The only chance we have to find better therapies for complex diseases is for the global scientific community to work together, and I value being part of that process.”

The Kuwait Prize was first awarded in 1979 and has grown in stature ever since its introduction. Award recipients are selected based on evaluations from local and international scientific institutions. Each prize winner receives approximately $130,000 USD, a gold medal presented by the Emir of Kuwait (Sheikh Sabah Al-Ahmad Al-Jaber Al-Sabah), a KFAS shield, and a certificate of recognition.

PRI Celebrates 15 Years !!

Left to Right: W. Li, K. Godugu, S.A. Mousa, P. Phillips. M. Jayaraman, D. Bharali, S. Thangirala,

M. Rajabi, B. Hay, K. Keating, O. Karakus


SEPTEMBER 25, 2017 – Click here for full brochure and schedule 


Left to right, Dr. Weikun Li (PRI), Dr. Mousa, Dr. Kavitha Godugu (PRI)

Dr. Li’s poster was titled, “Formulation and pharmacokinetics of diamino propane tetraiodothyroacetic acid-conjugated biodegradable polymeric nanoparticles and anti-angiogenesis efficacy” with coauthors Murat Yalcin, Dhruba J. Bharali, Quishan Lin, Kavitha Godugu, and Shaker A. Mousa.

Dr. Godugu’s poster was titled, “Anticancer Efficacy of P-bi-TAT, A Novel Thyrointegrin Receptor Antagonist in Solid Tumors” with coauthors Sudha Thangirala, Mehdi Rajab, and Shaker A. Mousa.

Recent Publications

  • Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac

    T Sudha, DJ Bharali, M Yalcin, NHE Darwish, M Debreli Coskun, KA Keating, H-Y Lin, PJ Davis, SA Mousa (2017)
    Nanomedicine 12(3):195-205.

    Read more
  • Self-assembly of green tea catechin derivatives in nanoparticles for oral lycopene delivery

    W Li, M Yalcin, Q Lin, MM Ardawi, SA Mousa (2017)
    Journal of Controlled Release 248:117-124

    Read more